NCT01895855View on ClinicalTrials.gov

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

PHASE3CompletedINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Cholera
Interventions
BIOLOGICAL

PXVX0200

Single dose; liquid suspension after reconstitution with buffer; 5x10\^8

BIOLOGICAL

placebo

Trial Locations (3)

21201

University of Maryland Baltimore, Baltimore

45229

Cincinnati Children'S Hospital Medical Center, Cincinnati

05405

University of Vermont, Burlington

Sponsors

Lead Sponsor

Bavarian Nordic

Collaborators (1)

Emergent BioSolutions
All Listed Sponsors
collaborator

Emergent BioSolutions

INDUSTRY

lead

Bavarian Nordic

INDUSTRY